Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
Abstract Background The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) can improve progres...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40164-018-0103-z |